EarningsQ2 2026 Earnings Report
MX:CRDAN Q2 2026 EPS Results
Actual EPS$18.30
Consensus EPS$18.19
Beat/MissBeat by +$0.12
One Year Ago EPS$16.86
MX:CRDAN Q2 2026 Revenue Results
Actual Revenue$20.56B
Expected Revenue$10.37B
Beat/MissBeat by +$10.19B
YoY Revenue Growth+2.89%
Earnings Announcement Details
QuarterQ2 2026
Date07/28/2026
TimeBefore Open
Conference CallTuesday, July 28, 2026
MX:CRDAN Upcoming Earnings
Croda International's next earnings date is estimated for February 23, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: organic growth, margin expansion, improved EPS and cash flow, strong outperformance in Consumer Care (notably Beauty Actives) and progress on transformation and AI initiatives. Headwinds remain in certain areas — Pharma Solutions phasing and lumpiness, Crop Protection weakness, regional F&F disruption, working-capital outflow and input-cost volatility — but management reiterated FY guidance and a clear path to their 3-year targets, viewing many challenges as within management control.Company Guidance
Revenue and Sales Growth
Group sales up 5% in constant currency to GBP 881m in H1; volumes +1% and price/mix +4%; organic sales guidance reiterated at 3–6% for FY2026.
Profitability and EPS Expansion
Adjusted operating profit up 7% to GBP 156m; adjusted operating margin expanded from 17.2% to 17.7% (50 bps); EPS up 9% to 78p.
Free Cash Flow and Balance Sheet
Free cash flow improved to GBP 38m (from GBP 28m prior year); net debt GBP 578m with conservative leverage at 1.4x EBITDA; interim dividend declared at 48p.
Strong Consumer Care and Beauty Actives Performance
Consumer Care up 8% and Beauty Actives standout: Volufiline/actives momentum with Beauty Actives growth of 27% in Q2; ceramides sales up 44% in H1; evidence of successful internationalization and customer adoption.
Pharma Ingredients Growth
Pharma Ingredients grew 7% in H1, with customer co-creation and flagship ingredient relaunches gaining traction; advanced ingredients (e.g., Virodex) showing early commercial success.
Transformation Savings and Margin Contribution
Transformation delivered GBP 18m of cost savings in the half (c.2 percentage points of margin expansion); cumulative transformation benefits GBP 46m; working-capital program targeting ~GBP 50m structural savings by 2028.
Capital Deployment and Capacity Expansion in Asia
CapEx reduced to GBP 43m (following heightened investment); two new sites opened in Dahej, India and Guangzhou, China to support faster growth in Asia.
Digital/AI and Operational Efficiency Gains
AI-led seed business improvement achieved a fivefold reduction in treatment times using 20+ years of data, generating incremental revenue; company embedding AI across R&D and operations to speed innovation cycles.
MX:CRDAN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed